RNA Splicing
Merck KGaA Forms $2 Billion Neurological Disease Pact with Skyhawk Therapeutics
Merck KGaA; Skyhawk Therapeutics; neurological diseases; RNA splicing; SkySTAR platform; drug discovery; strategic collaboration; milestone payments
Actionable Insights Powered by AI
Merck KGaA; Skyhawk Therapeutics; neurological diseases; RNA splicing; SkySTAR platform; drug discovery; strategic collaboration; milestone payments